The European Medicines Agency (EMA) has issued draft guidance describing the types of evidence developers of gene therapies need to support marketing authorization — saying very small firms, which comprise the majority of this segment, may not be familiar with the regulatory process.
Source:: Drug Industry Daily
Leave a Reply